Overview
International law firm McDermott Will & Emery represented Prime Therapeutics LLC, a diversified pharmacy solutions organization serving health plans, employers and government programs, in connection with its acquisition of Magellan Rx Management, the pharmacy division of Magellan Health, from Centene Corporation for $1.35 billion. The agreement unites Prime’s strong foundation of pharmacy benefit management (PBM) capabilities with Magellan Rx’s industry-leading total specialty drug management expertise to create a diversified pharmacy solutions organization serving commercial markets and government programs.
The McDermott team was led by Jeremy Earl, Mark Mihanovic, and Diego Gomez-Cornejo. Elaine Kao, Nicole Yoon, Joseph Mansilla and Kan Lew advised on corporate matters. Mimi Alexandre, Kate McDonald, Adam Marks, Simone Hussassian, Karen Gibbs, Grayson Dimick, Taylor Hood, Emily Curran, Greg Mitchell, Scott Weinstein, Sam Siegfried, Emily Cook, Dan Graham and Llewelyn Engel advised on healthcare regulatory and data privacy matters. Andrew Liazos, Jacob Mattinson and Teal Trujillo advised on employee benefits matters. Michelle Strowhiro, Abigail Kagan, Melis Solaksubasi and Dawn Peacock advised on labor and employment matters. Stephen Wu, Dan Powers and Anthony Ferrara advised on antitrust matters. Daniel Zucker, Alex Farr, Eric Carstens and Diann Smith advised on tax matters. Sarah Bro, Shawn Helms and Raja Chatterjee advised on intellectual property matters. Mark Bilut advised on environmental matters and Kristi Mankowske advised on real estate matters.
Read Prime Therapeutic’s press release here.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
